instead of focusing litigation on whether or not the generic manufacturers are actively PROMOTING their “skinny labeled” generic for patent-protected reduce-it IP uses,
the argument could be made that by PRODUCING generic icosapent ethyl in a quantity in excess of that required to fulfill Rxs to treat the MARINE indication, the generic manufacturers are inducing infringement on the reduce-it IP.